Kamada (NASDAQ:KMDA) Share Price Crosses Below 200-Day Moving Average – Time to Sell?

Kamada Ltd. (NASDAQ:KMDA) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $8.02 and traded as low as $7.05. Kamada shares last traded at $7.26, with a volume of 65,733 shares changing hands.

Analyst Ratings Changes

KMDA has been the subject of a number of recent research reports. Stifel Nicolaus set a $11.00 target price on Kamada in a research report on Wednesday, March 11th. Wall Street Zen cut Kamada from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Finally, Weiss Ratings lowered Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $12.00.

Kamada Stock Performance

The stock’s 50 day moving average is $7.78 and its 200 day moving average is $8.02. The company has a market capitalization of $417.52 million, a PE ratio of 20.74, a PEG ratio of 0.67 and a beta of 0.83.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.73%. The business had revenue of $45.24 million during the quarter, compared to analysts’ expectations of $46.72 million. On average, equities research analysts forecast that Kamada Ltd. will post 0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Kamada

Several hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in Kamada during the 1st quarter worth about $582,000. Goldman Sachs Group Inc. bought a new stake in shares of Kamada during the first quarter valued at about $497,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Kamada in the second quarter worth about $472,000. Bank of America Corp DE lifted its holdings in shares of Kamada by 201.0% in the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after buying an additional 41,111 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Kamada by 25.9% in the fourth quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 40,514 shares in the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.